标题
Treating Prostate Cancer by Antibody–Drug Conjugates
作者
关键词
-
出版物
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 22, Issue 4, Pages 1551
出版商
MDPI AG
发表日期
2021-02-05
DOI
10.3390/ijms22041551
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Epigenetic modulations and lineage plasticity in advanced prostate cancer
- (2020) R. Ge et al. ANNALS OF ONCOLOGY
- Cancer statistics, 2020
- (2020) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Systemic Treatment for Metastatic Hormone Sensitive Prostate Cancer: A Comprehensive Meta-Analysis Evaluating Efficacy and Safety in Specific Sub-Groups of Patients
- (2020) Vincenzo Di Nunno et al. CLINICAL DRUG INVESTIGATION
- A Systematic Review and Network Meta-Analysis of Novel Androgen Receptor Inhibitors in Non-metastatic Castration-Resistant Prostate Cancer
- (2020) Amanda E. Hird et al. Clinical Genitourinary Cancer
- Trop2 is a driver of metastatic prostate cancer with neuroendocrine phenotype via PARP1
- (2020) En-Chi Hsu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Cryo-EM structure and potential enzymatic function of human six-transmembrane epithelial antigen of the prostate 1
- (2020) Wout Oosterheert et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for nonmetastatic castration-resistant prostate cancer (nmCRPC).
- (2020) Karim Fizazi et al. JOURNAL OF CLINICAL ONCOLOGY
- Olaparib for Metastatic Castration-Resistant Prostate Cancer
- (2020) Johann de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer
- (2020) Cora N. Sternberg et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sacituzumab Govitecan: First Approval
- (2020) Yahiya Y. Syed DRUGS
- High B7‐H3 expression is linked to increased risk of prostate cancer progression
- (2020) Sarah Bonk et al. PATHOLOGY INTERNATIONAL
- Current Strategies and Novel Therapeutic Approaches for Metastatic Urothelial Carcinoma
- (2020) Veronica Mollica et al. Cancers
- New Frontiers in Prostate Cancer Treatment: Are We Ready for Drug Combinations with Novel Agents?
- (2020) Gaetano Aurilio et al. Cells
- B7-H3: an attractive target for antibody-based immunotherapy
- (2020) Filippos Kontos et al. CLINICAL CANCER RESEARCH
- Predicting future cancer burden in the United States by artificial neural networks
- (2020) Francesco Piva et al. Future Oncology
- Phase 1 study of PSMA ADC, an antibody-drug conjugate targeting prostate-specific membrane antigen, in chemotherapy-refractory prostate cancer
- (2019) Daniel P. Petrylak et al. PROSTATE
- Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer
- (2019) Karim Fizazi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Treatment of Advanced Prostate Cancer
- (2019) Min Yuen Teo et al. Annual Review of Medicine
- Imaging metastatic castration-resistant prostate cancer patients with 89Zr-DFO-MSTP2109A anti-STEAP1 antibody
- (2019) Jorge A. Carrasquillo et al. JOURNAL OF NUCLEAR MEDICINE
- ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer
- (2019) Andrew J. Armstrong et al. JOURNAL OF CLINICAL ONCOLOGY
- Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer
- (2019) Ian D. Davis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Antibody–drug conjugates for cancer
- (2019) Cindy H Chau et al. LANCET
- Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer
- (2019) Ronald de Wit et al. NEW ENGLAND JOURNAL OF MEDICINE
- Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer
- (2019) E J Small et al. ANNALS OF ONCOLOGY
- Antibody-Drug Conjugates: A Comprehensive Review
- (2019) Puregmaa Khongorzul et al. MOLECULAR CANCER RESEARCH
- Phase I Study of DSTP3086S, an Antibody-Drug Conjugate Targeting Six-Transmembrane Epithelial Antigen of Prostate 1, in Metastatic Castration-Resistant Prostate Cancer
- (2019) Daniel C. Danila et al. JOURNAL OF CLINICAL ONCOLOGY
- Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol
- (2018) M R Sydes et al. ANNALS OF ONCOLOGY
- Resistance to Antibody–Drug Conjugates
- (2018) Sara García-Alonso et al. CANCER RESEARCH
- Recent Advances in Prostate Cancer Treatment and Drug Discovery
- (2018) Ekaterina Nevedomskaya et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Knockdown of STEAP1 inhibits cell growth and induces apoptosis in LNCaP prostate cancer cells counteracting the effect of androgens
- (2018) Inês Margarida Gomes et al. MEDICAL ONCOLOGY
- Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer
- (2018) Maha Hussain et al. NEW ENGLAND JOURNAL OF MEDICINE
- Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer
- (2018) Matthew R. Smith et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abstract 820: Preclinical development of MGC018, a duocarmycin-based antibody-drug conjugate targeting B7-H3 for solid cancer
- (2018) Juniper A. Scribner et al. CANCER RESEARCH
- Managing Nonmetastatic Castration-resistant Prostate Cancer
- (2018) Joaquin Mateo et al. EUROPEAN UROLOGY
- Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade
- (2018) Wassim Abida et al. JAMA Oncology
- 177 Lu-PSMA Radioligand Therapy for Prostate Cancer
- (2017) Wolfgang P. Fendler et al. JOURNAL OF NUCLEAR MEDICINE
- Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
- (2017) Karim Fizazi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inhibition of Intercellular Communication between Prostate Cancer Cells by A Specific Anti-STEAP-1 Single Chain Antibody
- (2017) Seyed-Alireza Esmaeili et al. Anti-Cancer Agents in Medicinal Chemistry
- AR-V7 and prostate cancer: The watershed for treatment selection?
- (2016) Chiara Ciccarese et al. CANCER TREATMENT REVIEWS
- Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort
- (2016) Matthew R. Smith et al. EUROPEAN UROLOGY
- Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
- (2016) Howard I. Scher et al. JOURNAL OF CLINICAL ONCOLOGY
- Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer
- (2016) Colin C. Pritchard et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase 1/2 multiple ascending dose trial of the prostate-specific membrane antigen-targeted antibody drug conjugate MLN2704 in metastatic castration-resistant prostate cancer
- (2016) Matthew I. Milowsky et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
- (2015) Charles J Ryan et al. LANCET ONCOLOGY
- Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
- (2015) Christopher J. Sweeney et al. NEW ENGLAND JOURNAL OF MEDICINE
- Magnitude of PD-1, PD-L1 and T Lymphocyte Expression on Tissue from Castration-Resistant Prostate Adenocarcinoma: An Exploratory Analysis
- (2015) Francesco Massari et al. Targeted Oncology
- Trop-2 is up-regulated in invasive prostate cancer and displaces FAK from focal contacts
- (2015) Marco Trerotola et al. Oncotarget
- Neuroendocrine differentiation in prostate cancer: Novel morphological insights and future therapeutic perspectives
- (2014) Matteo Santoni et al. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
- Antibody-drug conjugates targeting prostate-specific membrane antigen
- (2014) William Olson Frontiers in Bioscience-Landmark
- Prostate cancer relevant antigens and enzymes for targeted drug delivery
- (2014) Ashutosh Barve et al. JOURNAL OF CONTROLLED RELEASE
- Managing bone metastases and reducing skeletal related events in prostate cancer
- (2014) Benjamin A. Gartrell et al. Nature Reviews Clinical Oncology
- Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
- (2014) Tomasz M. Beer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Androgen receptors in hormone-dependent and castration-resistant prostate cancer
- (2013) Ayesha A. Shafi et al. PHARMACOLOGY & THERAPEUTICS
- Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
- (2012) Howard I. Scher et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
- (2012) Charles J. Ryan et al. NEW ENGLAND JOURNAL OF MEDICINE
- CD46 in innate and adaptive immunity: an update
- (2011) J. Cardone et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Abiraterone and Increased Survival in Metastatic Prostate Cancer
- (2011) Johann S. de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
- (2010) Johann Sebastian de Bono et al. LANCET
- Phase I Trial of the Prostate-Specific Membrane Antigen–Directed Immunoconjugate MLN2704 in Patients With Progressive Metastatic Castration-Resistant Prostate Cancer
- (2008) Matthew D. Galsky et al. JOURNAL OF CLINICAL ONCOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now